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A B S T R A C T
Background
Paraproteinaemic neuropathy refers to those neuropathies associatedwith amonoclonal gammopathy or paraprotein. Themost common
of these present with a chronic, predominantly sensory, symmetrical neuropathy, similar to chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) but with relatively more sensory involvement, both clinically and neurophysiologically. The optimal
treatment for neuropathies associated with IgG and IgA monoclonal gammopathy of uncertain significance is not known. This is an
update of a review first published in 2007.
Objectives
To assess the effects of any treatment for IgG or IgA paraproteinaemic peripheral neuropathy.
Search methods
On 18 January 2014 we searched the Cochrane Neuromuscular Disease Group Trials Specialized Register, CENTRAL, MEDLINE and
EMBASE. We also checked bibliographies for controlled trials of treatments for IgG or IgA paraproteinaemic peripheral neuropathy.
We checked clinical trials registries for ongoing studies in November 2014.
Selection criteria
We considered for inclusion randomised controlled trials (RCTs) and quasi-RCTs using any treatment for IgG or IgA paraproteinaemic
peripheral neuropathy. We excluded people with IgM paraproteins. We excluded people where the monoclonal gammopathy was
considered secondary to an underlying disorder. We included participants of any age with a diagnosis of monoclonal gammopathy of
uncertain significance with a paraprotein of the IgG or IgA class and a neuropathy. Included participants were not required to fulfil
specific electrophysiological diagnostic criteria.
Data collection and analysis
We used standard Cochrane methodology to select studies, extract data and analyse results. One trial author provided additional data
and clarification.
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Main results
We identified one RCT, with 18 participants, that fulfilled the predetermined inclusion criteria. The trial compared plasma exchange to
sham plasma exchange in participants with IgG or IgA paraproteinaemic neuropathy over a three-week follow-up period. We identified
four other studies but these were not RCTs or quasi-RCTs. The included RCT did not report our predefined primary outcome measure,
change in disability six months after randomisation. The trial revealed a modest benefit of plasma exchange in the weakness component
of the Neuropathy Disability Score (NDS, now the Neuropathy Impairment Score); the mean improvement with plasma exchange was
17 points (95% confidence interval (CI) 5.2 to 28.8 points) versus 1 point (95% CI -7.7 to 9.7 points) in the sham exchange group at
three weeks’ follow-up (mean difference (MD) 16.00; 95%CI 1.37 to 30.63, low quality evidence). There was no statistically significant
difference in the overall NDS (MD 18.00; 95% CI -2.03 to 38.03, low quality evidence), vibration thresholds or neurophysiological
indices. Adverse events were not reported. The trial was at low risk of bias overall, although limitations of trial size and duration reduce
the quality of the evidence in support of its conclusions.
Authors’ conclusions
The evidence fromRCTs for the treatment of IgG or IgA paraproteinaemic neuropathy is currently inadequate.More RCTs of treatments
are required. These should have adequate follow-up periods and contain larger numbers of participants, perhaps through multicentre
collaboration, considering the relative infrequency of this condition. Observational or open trial data provide limited support for
the use of treatments such as plasma exchange, cyclophosphamide combined with prednisolone, intravenous immunoglobulin, and
corticosteroids. These interventions show potential therapeutic promise but the potential benefits must be weighed against adverse
effects. Their optimal use and the long-term benefits need to be considered and validated with well-designed RCTs.
P L A I N L A N G U A G E S U M M A R Y
Treatment for neuropathies associated with abnormal antibodies in the blood (IgG and IgA paraproteinaemic neuropathies)
Review question
What are the benefits and harms of treatments for nerve damage associated with abnormal IgG and IgA proteins in the blood?
Background
Paraproteinaemic neuropathy refers to those neuropathies associated with a paraprotein (an abnormal antibody or immunoglobulin
(Ig) present in relative excess in the blood). Paraproteins come from a group of blood disorders called monoclonal gammopathies. If the
paraprotein is present without evidence of any underlying disease, this is known as a monoclonal gammopathy of uncertain significance
(MGUS). This review looked at the treatments for neuropathy associated with and possibly caused by IgG and IgA paraproteins. The
optimal treatment is not known. Treatments that act on the immune system such as plasma exchange, corticosteroids or intravenous
immunoglobulin have been examined in nonrandomised studies of people with IgG and IgA paraproteinaemic neuropathy.
Study characteristics
We identified only one randomised controlled trial (RCT), which compared plasma exchange with sham exchange, in 18 participants
with either IgA or IgG paraproteinaemic neuropathy. The results were reported after three weeks of treatment.
Key results and quality of the evidence
The trial did not report our primary outcome measure, which was improvement in disability measured by a validated scale six months
after randomisation, or our other specified outcomes at sixmonths. The trial demonstrated amodest benefit in improvement of weakness
and overall disability as measured by the neuropathy disability score (NDS) over a period of three weeks. There was no improvement
in this timescale in measures of sensory disturbance or electrical studies of the nerves. Adverse events were not reported. Further RCTs
of this and other treatments with larger numbers of participants are needed.
This is an update of a review first published in 2007. We found no additional trials for inclusion. The evidence is current to January
2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Plasma exchange (PE) versus sham exchange for IgG and IgA paraproteinaemic neuropathy
Patient or population: people with IgG and IgA paraproteinaemic neuropathy
Settings: hospital, ambulatory care
Intervention: plasma exchange
Comparison: sham exchange
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham exchange Plasma exchange
Change in disability
Neuropathy Disability
Score
Follow-up: 3 weeks1
The mean improvement
in disability in the control
group was
2 points
Themean improvement in
disability in the interven-
tion groups was
18 points higher
(2.03 lower to 38.03
higher)
18
(1 study)
⊕⊕©©
low2
A higher score is less dis-
ability (impairment)
Change in sensation us-
ing a validated scale (e.
g. INCAT sensory sum
score) - not measured
See comment See comment Not estimable - See comment Not an outcome in the in-
cluded study (Dyck 1991)
Change in strength
Neuropathy Disability
Score (weakness)
Follow-up: 3 weeks1
The mean improvement
in strength in the control
group was
1 point
Themean improvement in
strength in the interven-
tion groups was
16 points higher
(1.37 to 30.63 higher)
18
(1 study)
⊕⊕©©
low2
A higher score is less
weakness
Adverse events - not re-
ported
See comment See comment Not estimable - See comment Not reported in (Dyck
1991)
3
T
re
a
tm
e
n
t
fo
r
Ig
G
a
n
d
Ig
A
p
a
ra
p
ro
te
in
a
e
m
ic
n
e
u
ro
p
a
th
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; INCAT: Inflammatory Neuropathy Cause and Treatment
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Our prespecified time point was six months. We report three-week outcomes here; this was the duration of the included study.
2We found one randomised controlled trial, with a small number of participants (serious imprecision) and outcome measured after three
weeks instead of the more relevant six months pre-specified for this review (serious indirectness). It is unclear if paraprotein is incidental
or causative in neuropathies treated.
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B A C K G R O U N D
Paraproteinaemic neuropathy refers to a group of neuropathies as-
sociated with a monoclonal gammopathy or paraprotein. A para-
protein is an immunoglobulin (Ig) molecule produced by a mon-
oclonal plasma cell expansion. The monoclonal protein is present
in relative excess and is often nonfunctional. If the monoclonal
protein is present without evidence of an underlying causative dis-
ease, this is known as a monoclonal gammopathy of uncertain
significance (MGUS). Treatment for IgM paraprotein-associated
neuropathy has been reviewed previously (Lunn 2012). The treat-
ment of neuropathies occurring in people with IgG or IgAMGUS
is covered in this review.
Where the only clinical manifestation of the MGUS is neuropa-
thy, the neuropathy dictates treatment (Nobile-Orazio 2002), as
themonoclonal gammopathy usually remains benign and nonpro-
gressive. Kyle found that one per cent per year of all people with
MGUS progressed to develop a malignant plasma cell dyscrasia
(Kyle 1993). In Ponsford’s series of 50 people with IgG or IgA
MGUS neuropathy, six per cent developedmalignancy after a me-
dian follow-up of 14 years (Ponsford 2000). Others have found
malignant transformation more often occurs earlier in the natu-
ral history of MGUS in people with neuropathy and is associ-
ated with worsening neuropathy (Eurelings 2001).WhereMGUS
transforms into myeloma, the malignancy is more likely to deter-
mine treatment.
The prevalence of MGUS increases with age. The most common
paraprotein type is IgG, accounting for 61% of cases in one review
(Kyle 1992).Most people withMGUS do not have a symptomatic
neuropathy. Kelly found a monoclonal protein in 10% of people
with neuropathy of unknown aetiology (Kelly 1981). Conversely,
in series of people with MGUS, the prevalence of symptomatic
neuropathy ranged from 1% to 36% and was higher in MGUS
associated with IgM than with IgG or IgA paraproteins (Gosselin
1991; Nobile-Orazio 2002; Vrethem 1993; Yeung 1991).
Typically, paraproteinaemic neuropathy affects men in their sixth
to eighth decade. It presents with a chronic, predominantly sen-
sory, symmetrical neuropathy, similar to chronic inflammatory de-
myelinatingpolyradiculoneuropathy (CIDP). PeoplewithMGUS
neuropathy (IgM, IgG and IgA) often have less weakness and rel-
atively more sensory involvement, both clinically and neurophys-
iologically, than do people with idiopathic CIDP (Gorson 1997b;
Simmons 1993; Simmons 1995). Some have found less clinical or
neurophysiological sensory involvement in IgG and IgA parapro-
teinaemic neuropathy compared to IgM (Magy 2003; Notermans
2000). There is some diagnostic controversy, and debate continues
about whether a person with an IgG MGUS and otherwise typ-
ical CIDP justifies a separate diagnosis (Bleasel 1993; Simmons
1995); some authors classify it as a concurrent illness with CIDP
(EFNS/PNS 2010; Saperstein 2001). Some have found a dif-
ference in the clinical features between people with IgM and
IgG MGUS neuropathy (Gosselin 1991; Nobile-Orazio 1992;
Vrethem 2010), but others have not (Bromberg 1992; Yeung
1991).
The majority of the cases reported in the literature are associated
with IgG as opposed to IgA. The clinical and electrophysiologi-
cal features of 205 IgG and 27 IgA reported cases have been re-
viewed (Nobile-Orazio 2002). The review highlights the hetero-
geneity of both IgG and IgA MGUS neuropathy patients, noted
previously in smaller studies by others (Di Troia 1999; Gorson
1997a; Hermosilla 1996; Notermans 1994). People with IgG and
IgA paraproteinaemic neuropathy have either demyelinating or ax-
onal/mixed neuropathies, in approximately equal numbers. Those
with a slowly progressive distal axonal polyneuropathy tend to
show a poor response to immunotherapy (treatments that have
a mechanism of action via modulation of the immune system).
Others with a sensorimotor demyelinating neuropathy frequently
respond to immunotherapy (Magy 2003).
Initial screening with serum protein electrophoresis is nonspecific
but may identify the presence of a serum paraprotein in higher
concentrations. Immunofixation is required to detect those at low
concentrations (< 0.2 g/L), which may not be detected by elec-
trophoresis. Immunofixation is also necessary to identify the exact
isotype of the heavy and light chains. Occasionally light chains in
the urine can identify the presence of a serum paraprotein.
The pathogenic role of IgG and IgA paraproteins is debated. Mon-
oclonal gammopathy may become apparent after the onset of neu-
ropathy (Nobile-Orazio 1992; Simmons 1995). Serum levels of
the paraprotein fluctuate and may not correlate with the clinical
course (Bleasel 1993). Some researchers have suggested that the
paraprotein is part of a secondary autoimmune response (Di Troia
1999).Others argue that it is a coincidental finding, particularly in
the setting of a chronic axonal neuropathy (Kyle 1987; Notermans
1996a; Ritzmann 1975; Saleun 1982).
The paraprotein antibodies are sometimes found to have specific
antigen targeted activity. In people with IgG MGUS, Di Troia
et al. found no differences in the frequency of antibodies to var-
ious neural glycoprotein and glycolipid antigens between people
with and without neuropathy (Di Troia 1999). Others have found
antibodies to neurofilament antigens in people with neuropathy
(Fazio 1992; Stubbs 2003). The immunological characteristics of
people with IgG and IgA paraproteinaemic neuropathy have been
reviewed (Nobile-Orazio 2002). A few cases demonstrated IgA or
IgG deposition in the nerves (Bailey 1986; Mehndiratta 2004;
Vallat 2000), but the pathogenic significance of this finding re-
mains uncertain. In a histological study, sural nerve biopsies in
eight people with IgG paraproteins were indistinguishable from
those of idiopathic CIDP (Vital 2000). Other biopsy studies have
suggested more T cell involvement in paraproteinaemic neuropa-
thy (Eurelings 2002; Eurelings 2003) than in CIDP without a
paraprotein.
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The optimal treatment for IgG and IgA MGUS neuropathies is
not known. In two published observational studies people with
’CIDP-MGUS’ responded less well to immunotherapy than those
with idiopathicCIDP (Simmons 1993; Simmons 1995). In a third
study, the responses were similar (Gorson 1997b). A review of
124 people with IgG MGUS and neuropathy considered treat-
ment with immune therapies (most commonly corticosteroids and
plasma exchange) (Nobile-Orazio 2002). Of these 124 people,
67 had a demyelinating neuropathy and of these, 54 (81%) re-
sponded to immunotherapies, compared with only seven of 34
people (21%)with an axonal neuropathy. In the same review, seven
of 13 IgA cases responded to immune therapies. In a double-blind
controlled trial of plasma exchange versus shamplasma exchange in
39 participants with polyneuropathy associated with MGUS (21
IgM and 18 IgG/IgA), plasma exchange produced more marked
improvement in the neuropathy disability score (now referred to as
the neuropathy impairment score (Dyck 2005)) and neurophys-
iological improvement, in those with IgG or IgA (Dyck 1991).
Gorson reported improvement with IVIg in eight of 20 people
who had IgG MGUS (Gorson 2002). In one series of people with
axonal neuropathy and IgG MGUS, authors reported improve-
ment in one out of three people treated with corticosteroids (Di
Troia 1999).
This is an update of a review first published in 2007.
O B J E C T I V E S
To assess the effects of any treatment for IgG or IgA parapro-
teinaemic peripheral neuropathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi-RCTs
using any treatment for IgG or IgA paraproteinaemic peripheral
neuropathy.
Types of participants
We followed the International Myeloma Working Group 2003
diagnostic criteria for MGUS: monoclonal protein < 30 g/L and
clonal plasma cell population < 10% with no evidence of mul-
tiple myeloma, other B-cell proliferative disorders or amyloido-
sis (Myeloma 2003). We therefore excluded people in whom the
monoclonal gammopathy was considered to be due to an underly-
ing disorder, such asmultiple myeloma, plasmocytoma, malignant
lymphoproliferative diseases or amyloidosis.
We included people of any age who had a diagnosis of MGUS
with a paraprotein of the IgG or IgA class and a neuropathy. We
excluded individuals with IgM paraproteins. We also ruled out
other causes of peripheral neuropathy. The clinical picture was a
recognised presentation of peripheral neuropathy (Nobile-Orazio
2002), being typically a symmetrical sensory or sensorimotor neu-
ropathy. Neurophysiologically the neuropathy could be demyeli-
nating, axonal or of mixed type, and therefore it did not need to
fit any published electrophysiological diagnostic criteria. We in-
cluded studies that did not exactly fulfil these criteria, provided
the review authors agreed that IgG or IgA paraproteinaemic pe-
ripheral neuropathy was the preferred diagnosis, if necessary after
consultation with the original study authors. We noted any depar-
tures from the diagnostic criteria.
Types of interventions
We included any treatment used for IgG or IgA paraproteinaemic
peripheral neuropathy. Treatments could be administered using
various protocols (for example as a single agent, in combination
or sequentially). The control arm did not necessarily include a
placebo, but if the control arm received a treatment then the par-
ticipants in the experimental arm also had to have received that
same treatment. We considered any route of administration, pro-
vided that it had been defined. We also required dosages and the
frequency and length of administration to have been defined in
the studies.
Types of outcome measures
Primary outcomes
The predefinedprimary outcomemeasurewas: change in disability
at six months after randomisation, measured by a validated scale
such as the Overall Disability Scale (ODS) (Merkies 2003a).
We selected a disability score for the primary outcome, as such
scores are considered to be themost relevantmeasures in immune-
mediated neuropathies (Merkies 2003b). They are also potentially
easy to derive retrospectively fromcollected data.Wepredefined six
months as a favoured time point for re-evaluation, on the basis that
IgG or IgA paraproteinaemic peripheral neuropathy is a chronic
and slowly progressive or relapsing-remitting disorder. However,
to avoid limiting the scope of the review we considered trials using
other trial periods and follow-up intervals, and made appropriate
adjustments in our analysis.
Secondary outcomes
Secondary outcome measures were as follows.
1. Change at six months in sensation, measured by a validated
scale such as the Inflammatory Neuropathy Cause and
Treatment (INCAT) sensory sum score (Merkies 2000).
6Treatment for IgG and IgA paraproteinaemic neuropathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Change in strength at six months, measured by a validated
scale such as the Medical Research Council (MRC) sum score
(Kleyweg 1991).
3. Neurophysiology: change at six months, measured by the
distally evoked summed compound muscle action potential
(CMAP) amplitudes.
4. Neurophysiology: change at six months, measured by a
change in the number of sites of conduction block, as defined by
the American Association of Neurology diagnostic criteria for
CIDP (CIDP 1991).
5. Adverse events - adverse events defined as those which are
fatal, life threatening or required or resulted in hospitalisation.
We would have adjusted the rate for differing follow-up periods
as necessary.
Search methods for identification of studies
On 18 January 2014 we searched the Cochrane Neuromuscu-
lar Disease Group Trials Specialized Register, the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) (2013, Issue 12),
MEDLINE (January 1966 to January 2014) and EMBASE (Jan-
uary 1980 to January 2014). There were no language limitations.
We searched the US National Institutes for Health Clinical Tri-
als Registry, www.ClinicalTrials.gov and the World Health Orga-
nization International Clinical Trials Registry Portal (ICTRP) (
apps.who.int/trialsearch/) for ongoing studies on 18 November
2014.
Electronic searches
We provided the detailed search strategies in the appendices:
MEDLINE (Appendix 1), EMBASE (Appendix 2) and CEN-
TRAL (Appendix 3).
Searching other resources
We reviewed bibliographies to identify other controlled trials.
Data collection and analysis
Selection of studies
Two review authors (ACJS and NCN at this update) indepen-
dently checked titles and abstracts identified from the Cochrane
Neuromuscular Disease Group Specialized Register, MEDLINE
and EMBASE searches and bibliographies. The review authors
obtained the full texts of potentially relevant studies, and three
authors (ACJS,MPTL and NCN) carried out independent assess-
ments to decide which trials met the inclusion criteria. There were
no disagreements about study selection.
Data extraction and management
Two review authors (ACJS and NCN) independently extracted
data. An author of the included study provided some additional
data and clarification (Dyck 1991).
Assessment of risk of bias in included studies
The ’Risk of bias’ assessment took into account seven predefined
domains, namely sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome as-
sessment, incomplete outcome data, selective outcome reporting
and ‘other issues’. For each domain two review authors indepen-
dently made a judgement of ‘low risk of bias’, ‘high risk of bias’,
or ‘unclear risk of bias’ (Higgins 2011). There were no disagree-
ments.
Measures of treatment effect
The trial provided continuous data. We reported the mean dif-
ference (MD) in improvement from baseline, with corresponding
95% confidence interval (CI).
To allow meta-analysis where different trials used different mea-
surement scales for outcomes that were conceptually the same, we
would have either dichotomised changes or use standard devia-
tions (SDs) as the units and report standardised mean differences
with 95% CI, either using the SD of the population at baseline or
of the control population.
Data synthesis
We did not perform meta-analysis, test for heterogeneity across
trials or conduct the planned subgroup analyses described in the
protocol (Allen 2005) because of the lack of included trials and
the lack of data available.
We considered nonrandomised evidence concerning adverse
events, cost-effectiveness and treatments currently in use in the
Discussion.
We created a ’Summary of findings’ table using the following
outcomes: change in disability (NDS), change in strength (NDS
weakness) and change in sensation (INCAT sensory sum score).
We used the five Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) considerations (study limi-
tations, consistency of effect, imprecision, indirectness and publi-
cation bias) to assess the quality of a body of evidence (studies that
contribute data for the prespecified outcomes). We used methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) using GRADEpro software (GRADEpro 2008).
We justified all decisions to downgrade the quality of studies using
footnotes and we made comments to aid reader’s understanding
of the review where necessary.
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R E S U L T S
Description of studies
Results of the search
The number of papers found by the new, current strategies, which
were run on 18 January 2014, were:
• MEDLINE - 1343
• EMBASE - 478
• Cochrane Neuromuscular Disease Group Specialized
Register - 74
• CENTRAL - 113
We identified no additional published or unpublished data. The
systematic database searches in 2005 revealed five possible trials.
One trial met the inclusion criteria (Dyck 1991) (Characteristics
of included studies). We excluded the four other trials (see
Characteristics of excluded studies). The review authors identified
no new published or ongoing trials from the searches for this up-
dated review.
Included studies
There were 18 participants with IgG or IgA paraproteinaemic
neuropathy in the included trial (Dyck 1991). This trial was a
randomised double-blind, parallel-group, sham-controlled trial of
plasma exchange. The trial also included participants with IgM
paraproteinaemic neuropathy, but the report discussed results for
the different types of paraprotein separately, allowing the use of
these data. The criteria for the paraprotein specifically being a
MGUSwere not as strictly defined as those used for this review, but
we still considered that they fulfilled the criteria adequately. The
participants’ neuropathies were deemed to be either stable or wors-
ening at the time of enrolment. The intervention in this trial was a
twice-weekly 3.5 L plasma exchange for three weeks, totalling six
exchanges. No additional treatments were given. Participants re-
mained on other treatments that they were already taking but had
received no other immunotherapy in the six weeks prior to plasma
exchange. Eight participants with IgG or IgA paraproteinaemic
neuropathy initially received treatment. Ten control participants
with IgG or IgA paraproteinaemic neuropathy received full sham
exchanges, with plasma extraction, separation, recombination and
re-infusion. Nine of these control participants subsequently un-
derwent treatment with plasma exchange following the same pro-
tocol. The results of this open phase of the trial were also reported.
Excluded studies
We excluded the four remaining trials for various reasons:
Notermans 1996a performed an uncontrolled open prospective
trial of intermittent cyclophosphamide and prednisolone. Five of
the sixteen participants included had IgG MGUS neuropathy.
We also excluded a trial of pulsed high-dose dexamethasone as it
was an uncontrolled open trial of six participants with parapro-
teinaemic neuropathy (Notermans 1997). Only one had an IgG
MGUS, the others had IgMMGUS. Léger 1994 performed a trial
of IVIg that included four participants with IgG paraproteinaemic
neuropathy. This was an uncontrolled open prospective trial, for
which the diagnostic criteria were unclear, and which used no clear
outcome criteria. Sghirlanzoni 2000 reported a trial of 60 partici-
pants, which included nine with IgG paraproteinaemic neuropa-
thy. This trial included various immunosuppressant treatments.
The trial was a prospective, uncontrolled, nonrandomised cohort
study and the results for the IgG paraproteinaemic neuropathy
participants were not reported separately from those with an IgM
paraproteinaemic neuropathy.
Risk of bias in included studies
In Dyck 1991, participants underwent ’restricted randomisation’.
This was done to ensure that the baseline characteristics of age
and sex were approximately equal. The study authors state that
the groups at baseline were ’reasonably balanced’ with respect to
neuropathic abnormalities. We deemed the blinding process to
have been adequate and explicit clinical and outcome criteria to
have been used. We judged completeness of follow-up as partially
adequate, and therewere nodrop-outs. The study initially aimed to
include 40 participants, including participants with IgM MGUS
neuropathy. The results section describes 39 participants being
enrolled in the study and one developing myeloma. The results
state that the trial authors did not use the data for this participant
in the analysis. It is unclear whether this participant took part in
the trial or even underwent plasma exchange. The review authors
have presumed that the participant did not receive any treatment
and was not enrolled, consistent with the 39 participants that are
included in the baseline and post-treatment results. The follow-
up period was only three weeks.
Figure 1 summarises the review authors’ ’Risk of bias’ assessments.
8Treatment for IgG and IgA paraproteinaemic neuropathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Risk of bias summary: review authors’ judgements about each ’Risk of bias’ item for each included
study. Green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (-) = high risk of bias (not shown).
Effects of interventions
See: Summary of findings for the main comparison Plasma
exchange (PE) versus sham exchange for IgG and IgA
paraproteinaemic neuropathy
Plasma exchange versus sham exchange
The only eligible trial provided results for 18 participants with
IgG or IgA paraproteinaemic neuropathy at a follow-up interval
of three weeks (Dyck 1991). The trial authors did not separate
results with respect to the individual IgG or IgA subgroups. The
trial used the NDS (subsequently renamed the Neuropathy Im-
pairment Score) as the primary outcome measure. Scores could
range from zero to 244 points, with 244 being maximal neurolog-
ical disability (impairment). Included participants had an average
NDS of 60.5. The report provided neurophysiological improve-
ment data for the group but did not provide a neurophysiological
classification of the neuropathy (in terms of being predominantly
axonal or demyelinating) at baseline.
Primary outcome measure: change in disability
In the randomised controlled phase of the trial, the trial did not
report our predefined primary outcome measure, although it did
measure disability at three weeks. Comparing the overall NDS,
the treatment group improved by a mean of 20 points (95% CI
3.4 to 36.6) compared to 2 points (95% CI -9.2 to 13.2) for the
control group (MD 18.00; 95% CI -2.03 to 38.03; Analysis 1.1).
This was not statistically significant.
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Secondary outcome measures
Change in sensation
The trial authors did not report changes in sensation using a vali-
dated sum score as specified previously. Instead the trial measured
vibration detection thresholds at three weeks, and mean scores
were not statistically significantly better with plasma exchange
(MD 0.10; 95% CI -0.50 to 0.70; Analysis 1.2).
Change in strength
The trial also assessed strengthmeasurements at three weeks.Over-
all, the 19 participants (including those with IgM as well as IgG
and IgA paraproteins) who underwent plasma exchange improved
on average more than the 20 who underwent sham exchange. Par-
ticipants with IgG or IgA paraproteinaemic neuropathy improved
more in weakness (P value = 0.03) when compared to participants
with IgM paraproteins. When assessing the participants with IgG
or IgA in isolation, improvement in the weakness score of theNDS
was significantly greater in the eight participants given plasma ex-
change in comparison to the 10 given sham exchange. The plasma
exchange group showed mean score improvements of 17 (95% CI
5.2 to 28.8) versus 1 (95% CI -7.7 to 9.7) in the sham exchange
group (MD 16.00; 95% CI 1.37 to 30.63; Analysis 1.3). The re-
port did not specify the actual number of participants who showed
improvement.
Neurophysiology: change in CMAP amplitude
The mean scores for summed CMAPmeasurements were also not
statistically significantly different (MD 2.00 mV; 95%CI -0.94 to
4.94; Analysis 1.4). Subjective assessment was not recorded.Motor
nerve conduction studies showed no significant differences (MD
4.00 m/s; 95% CI -12.30 to 20.30; Analysis 1.5), and sensory
nerve studies were not reported on follow-up.
Neurophysiology: change in the number of sites with
conduction block
The number of sites with conduction block was not reported
Adverse events
Details of adverse events were not reported.
D I S C U S S I O N
Only one trial fulfilled the predetermined inclusion criteria (Dyck
1991). Four other studies were not RCTs but we have discussed
some of their findings. Dyck 1991 included 39 participants of
whom 18 had either IgG or IgA paraproteinaemic neuropathy.
The risk of bias was low. The blinding process was well described
and performed. The trial used clear outcome criteria but did not
report all of the data, and the time points used were much shorter
than our predefined criteria. Baseline characteristics were reason-
ably balanced; completeness of follow-up and randomisationwere,
however, only partially adequate, based upon the descriptions pro-
vided. The trial did not use our primary outcome measure, but did
use some of our secondary outcome measures. In particular, there
was a statistically significant but modest increase in strength with
plasma exchange compared to sham exchange. The small number
of participants limited the power of the trial. Adverse events were
not reported. Due to the limited number of participants and a
short follow-up period we rated the quality of the evidence pro-
vided by this trial as low following the GRADE working group
rating system (see Summary of findings for the main comparison).
In the open trial stage of Dyck 1991, not included in the re-
sults section above, nine of the 10 participants with IgG or IgA
paraproteinaemic neuropathy who had initially received sham ex-
change in the controlled trial, then received plasma exchange. This
group subsequently showed very similar overall mean improve-
ments when compared to those of the initial treatment group from
the randomised trial phase. However, when the NIS, the weakness
score of the NIS, vibration detection threshold score and summed
CMAP scores were compared to the nine participants own original
(sham control) scores, the results were not statistically significantly
different. The overall results from the open trial phase did reveal
some statistically significant findings but only when the results for
all the IgG, IgA and IgM participants were included. The assessing
physicians were unblinded at this stage.
Although not included in this review, a trial of intermittent cyclo-
phosphamide (300 mg/m2 body surface daily for four days) com-
bined with prednisone (40 mg/m2 body surface daily for five days)
in 16participants provided relevant data (Notermans 1996a). Four
of the five participants with IgG paraproteinaemic neuropathy im-
proved or stabilised following treatment, and this was maintained
for three years of follow-up. Of these five participants, two had
mixed axonal and demyelinating findings on motor nerve conduc-
tion studies and three had predominantly demyelinating findings.
Side effects were a severe but reversible leukopenia after one cycle
of cyclophosphamide and prednisolone in one participant, neces-
sitating withdrawal of treatment. Other participants suffered hair
loss and nausea.
Another trial, of pulsed high dose dexamethasone (40 mg/day
orally for four days, once a month, in up to six cycles) in six partic-
ipants with paraproteinaemic neuropathy, showed a stable Rankin
scale and a two-point improvement in the MRC sum score at fol-
low-up in the single participant with IgG paraproteinaemic neu-
ropathy (Notermans 1997). However, this participant, like two
others, developed proximal lower limb weakness as a side effect.
Electrophysiologically, the single participant with IgG parapro-
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teinaemic neuropathy had amixed axonal and demyelinating neu-
ropathy. Further enrolment in the studywas stopped due to serious
side effects in four out of six participants, with three experiencing
severe mood disturbance.
Other reviews and some of the retrospective series discussed be-
low provide support for the use of immunotherapy. In a review
which included 124 people with IgGMGUS neuropathy, Nobile-
Orazio found that 81% of the 67 people with a predominantly
demyelinating neuropathy responded favourably to therapies such
as steroids and plasma exchange (Nobile-Orazio 2002). In a ret-
rospective review of 20 people with IgG MGUS neuropathy who
all received intravenous immunoglobulin, Gorson 2002 found a
beneficial response in eight.
Other studies have reported beneficial responses in some patients
to various therapies (Di Troia 1999; Magy 2003; Yeung 1991).
In a retrospective observational study, Magy reported that eight
out of nine people experienced a sustained clinical improvement
with either corticosteroids, plasma exchange or intravenous im-
munoglobulin. Yeung reported that four out of five people with
IgG experienced a good response to corticosteroids in another ret-
rospective observational study. Four also received cytotoxic drugs
but without additional benefit. Three IgA patients treated with
corticosteroids (one with a concomitant cytotoxic drug) also im-
proved but another person treated with plasma exchange showed
no benefit. In one series of people with axonal neuropathy and
IgG MGUS reported by Di Troia, improvement was reported in
one out of three treated with corticosteroids.
This review has revealed that only one RCT relating to the treat-
ment of IgG or IgA paraproteinaemic neuropathy exists. This may
be partly due to the relatively low prevalence of this disease. Unfor-
tunately, retrospective reviews are potentially open to bias. They
are not blinded, often do not consistently report useful assess-
ment scores and are not controlled. Furthermore, people with a
demyelinating neuropathy associated with IgG or IgAmonoclonal
gammopathy are considered to have CIDP (European Federation
of Neurological Societies/Peripheral Nerve Society (EFNS/PNS)
criteria for CIDP) as far as they fulfil the diagnostic criteria for
CIDP. These people are considered eligible for RCTs on CIDP,
making the initiation of new RCTs specifically on polyneuropathy
associated with IgG or IgA monoclonal gammopathy less likely.
Searches were comprehensive and the review authors are confident
that they have identified eligible studies. The review methods do
not allow for the detection of rare adverse events, because of the
small numbers of trial participants with this rare condition.
Although not addressed in trials so far, evaluation of treatments
should be made in people with both predominantly axonal and
demyelinating neuropathies associated with IgG or IgA MGUS.
It is uncertain whether the presence or absence of electrophysio-
logical characteristics predict response to treatment.
In the UK the cost of five single plasma volume plasma exchange
procedures is about the same as a course of IVIg 2.0 g/kg, namely
about GBP 4000. Patients may require multiple courses of plasma
exchange, each possessing inherent risks. In a large series of plasma
exchange for various indications, adverse reactions, including cit-
rate toxicity (3%), vasovagal reactions and vascular access compli-
cations, occurred in 3.9% of 17,940 procedures on 3583 people
(Kiprov 2001). As with any treatment the potential benefits of
plasma exchange treatment should be balanced against the costs
and potential side effects of that treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from randomised controlled trials for the treatment
of IgG or IgA paraproteinaemic neuropathy is currently inade-
quate. One small trial showed significant short-term benefit from
plasma exchange in measures of weakness but not in a composite
impairment score (NeuropathyDisability Score), sensory function
or neurophysiology measures. The long-term benefits and side ef-
fects of repeated plasma exchange have not been investigated.
Implications for research
More randomised controlled trials of existing and new treatments
are required. These should have adequate follow-up periods and
contain larger numbers of participants, perhaps throughmulticen-
tre collaboration because of the relative infrequency of this condi-
tion.
Future trials should use sensitive and validated disability and clin-
ical scores that are likely to extract meaningful effects (Merkies
2006). Quality of life assessment and cost effectiveness measure-
ments should also be considered in future studies, as the treat-
ments that have been used and those that are likely to be used in
the future are expensive. These treatments are also time consum-
ing to receive or provide, may be invasive and are not without side
effects. Trial endpoints should also be appropriate to the chronic-
ity of the disorder and meaningful in patient terms, particularly
overall disability. We had suggested a predefined endpoint of six
months or a year.
Some observational data provide limited support for the use
of plasma exchange, cyclophosphamide combined with pred-
nisolone, intravenous immunoglobulin and corticosteroids. Their
possible potential benefits must be weighed against their some-
times severe adverse effects. Their optimal use and long-term ben-
efits need to be considered and validated with well-designed ran-
domised controlled trials.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dyck 1991
Methods Parallel group, randomised double-blind sham controlled trial, with subsequent open
trial treatment for control participants
Participants 39 participants completed the trial. 18 of these had either IgA or IgG paraproteinaemic
neuropathy and were stable or deteriorating at the time of enrolment. 8 had plasma
exchange and 10 sham exchange
Interventions Plasma exchange. 3.5 L exchange, twice weekly for 3 weeks. Total of 6 exchanges
Outcomes Follow-up at 3 weeks. Outcomes were: Neuropathy Impairment Score, muscle weakness
score, vibrationdetection threshold and summedneurophysiological scores of compound
muscle action potentials, motor nerve conduction velocities and sensory nerve action
potentials
Notes Adverse events not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: patients were assigned... by re-
stricted randomization
Allocation concealment (selection bias) Low risk Quote: the only investigators not blinded
to treatment allocations were the patient
coordinator, the biostatistician and the
bloodbank consultant and personnel. The
patient and the examining physician were
unaware of the nature of the treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: a curtain separated the apheresis
equipment from the patient. For sham ex-
change, blood was drawn, separated into
cells and plasma...recombined, and rein-
fused
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: the only investigators not blinded
to treatment allocations were the patient
coordinator, the biostatistician and the
bloodbank consultant and personnel. The
patient and the examining physician were
unaware of the nature of the treatment
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Dyck 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: one patient was found to have os-
teoscleroticmyeloma and therefore the data
on this patient were not used in the analy-
sis. Neurophysiological data were provided
for 8 out of 18 participants
Selective reporting (reporting bias) Unclear risk Comment: insufficient information on
whether the selected outcome measures
were predefined
Other bias Low risk Comment: none found
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Léger 1994 Uncontrolled open prospective trial of intravenous immunoglobulin, including 4 participants with IgGMGUS
neuropathy. Diagnostic criteria unclear. No clear outcome criteria used
Notermans 1996 Uncontrolled open prospective trial of intermittent cyclophosphamide and prednisolone. 5 of the 16 participants
included had IgG MGUS neuropathy
Notermans 1997 Uncontrolled open trial of pulsed high-dose dexamethasone. Only 1 had an IgG MGUS neuropathy
Sghirlanzoni 2000 Prospective uncontrolled, nonrandomised cohort study. A trial of 60 participants, included 9 with IgG MGUS
neuropathy. Various immunosuppressant treatments included. Results for participants with IgG MGUS neu-
ropathy not reported separately from those with an IgM MGUS neuropathy
MGUS: monoclonal gammopathy of uncertain significance
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D A T A A N D A N A L Y S E S
Comparison 1. Plasma exchange (PE) versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in Neuropathy
Disability Score
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Change in Neuropathy
Disability Score (weakness)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Change in vibration detection
threshold
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Change in summed compound
muscle action potential
(CMAP) (mV)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Change in summed motor nerve
conduction velocity (m/s)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Plasma exchange (PE) versus control, Outcome 1 Change in Neuropathy
Disability Score.
Review: Treatment for IgG and IgA paraproteinaemic neuropathy
Comparison: 1 Plasma exchange (PE) versus control
Outcome: 1 Change in Neuropathy Disability Score
Study or subgroup PE Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1991 8 20 (24) 10 2 (18) 18.00 [ -2.03, 38.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-50 -25 0 25 50
Favours sham Favours PE
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Analysis 1.2. Comparison 1 Plasma exchange (PE) versus control, Outcome 2 Change in Neuropathy
Disability Score (weakness).
Review: Treatment for IgG and IgA paraproteinaemic neuropathy
Comparison: 1 Plasma exchange (PE) versus control
Outcome: 2 Change in Neuropathy Disability Score (weakness)
Study or subgroup PE Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1991 8 17 (17) 10 1 (14) 16.00 [ 1.37, 30.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-50 -25 0 25 50
Favours sham Favours PE
Analysis 1.3. Comparison 1 Plasma exchange (PE) versus control, Outcome 3 Change in vibration
detection threshold.
Review: Treatment for IgG and IgA paraproteinaemic neuropathy
Comparison: 1 Plasma exchange (PE) versus control
Outcome: 3 Change in vibration detection threshold
Study or subgroup Sham PE
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1991 10 0.1 (0.5) 7 0 (0.7) 0.10 [ -0.50, 0.70 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours sham Favours PE
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Analysis 1.4. Comparison 1 Plasma exchange (PE) versus control, Outcome 4 Change in summed
compound muscle action potential (CMAP) (mV).
Review: Treatment for IgG and IgA paraproteinaemic neuropathy
Comparison: 1 Plasma exchange (PE) versus control
Outcome: 4 Change in summed compound muscle action potential (CMAP) (mV)
Study or subgroup PE Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1991 5 0.4 (3) 9 -1.6 (2) 2.00 [ -0.94, 4.94 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-10 -5 0 5 10
Favours sham Favours PE
Analysis 1.5. Comparison 1 Plasma exchange (PE) versus control, Outcome 5 Change in summed motor
nerve conduction velocity (m/s).
Review: Treatment for IgG and IgA paraproteinaemic neuropathy
Comparison: 1 Plasma exchange (PE) versus control
Outcome: 5 Change in summed motor nerve conduction velocity (m/s)
Study or subgroup PE Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1991 3 -2 (13) 5 -6 (8) 4.00 [ -12.30, 20.30 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-50 -25 0 25 50
Favours sham Favours PE
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A P P E N D I C E S
Appendix 1. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to January Week 2 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (358644)
2 controlled clinical trial.pt. (86849)
3 randomized.ab. (259903)
4 placebo.ab. (140993)
5 drug therapy.fs. (1648210)
6 randomly.ab. (185772)
7 trial.ab. (267479)
8 groups.ab. (1200237)
9 or/1-8 (3085266)
10 exp animals/ not humans.sh. (3863199)
11 9 not 10 (2622734)
12 exp “Hereditary Motor and Sensory Neuropathies”/ (4894)
13 exp Peripheral Nervous System Diseases/ (111767)
14 peripheral nervous system disease$.tw. (113)
15 polyradiculoneuropath$.mp. (4855)
16 paraprotein$ peripheral neuropath$.mp. (3)
17 chronic demyelinat$ neuropath$.mp. (48)
18 chronic$ inflammatory demyelinat$ polyradiculoneuropath$.mp. (515)
19 exp Demyelinating Diseases/ (75068)
20 demyelinat$ disease$.tw. (4295)
21 or/12-20 (176286)
22 Monoclonal Gammopathies, Benign/ or exp Paraproteinemias/ or MGUS.mp. (40448)
23 exp Immunoglobulin A/ or exp Immunoglobulin G/ or exp PARAPROTEINS/ (142301)
24 Myelin-Associated Glycoprotein/ or MAG.mp. (3464)
25 or/22-24 (179430)
26 21 and 25 (6909)
27 ((IgG-MGUS or IgA-MGUS or IgA or IgG or Immunoglobulin G or Immunoglobulin A or paraprotein$ or monoclonal gam-
mopath$ or MAG or (myelin and glycoprotein$)) and (((demyelinat$ or peripheral) and (nerv$ or neuro$)) or (radiculoneuropath$
or polyradiculoneuropath$ or polyneuropath$ or neuropath$))).mp. (5215)
28 26 or 27 (9782)
29 (intervention or treatment).mp. (3161497)
30 exp Therapeutics/ (3256670)
31 (rituximab or plasma exchange or plasmapheresis or fludarabine or azathioprine or cyclosporine ormethotrexate or prednisolone).mp.
(145508)
32 exp cyclophosphamide/ (46176)
33 exp dexamethasone/ (43145)
34 exp interferons/ (110039)
35 exp adrenal cortex hormones/ (329196)
36 (stem cell adj2 transplantation).mp. (55373)
37 (Intravenous adj2 immunoglobulin$).mp. (12461)
38 (ivig or interferon$1 or cyclophosphamide or dexamethasone or corticosteroid$).tw. (252798)
39 or/29-38 (5671547)
40 11 and 28 and 39 (1771)
41 40 not (ms or multiple sclerosis).mp. (1356)
42 remove duplicates from 41 (1343)
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Appendix 2. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2014 Week 03>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure/ (39502)
2 double-blind procedure/ (119737)
3 randomized controlled trial/ (364698)
4 single-blind procedure/ (18828)
5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$
or allocat$ or volunteer$).tw. (1326805)
6 or/1-5 (1410344)
7 exp animals/ (19245302)
8 exp humans/ (15189009)
9 7 not (7 and 8) (4056293)
10 6 not 9 (1267260)
11 limit 10 to embase (980920)
12 Hereditary Motor Sensory Neuropathy/ (6413)
13 exp Peripheral Neuropathy/ (50281)
14 peripheral$ nervous$ system$ disease$.tw. (146)
15 polyradiculoneuropath$.tw. (1513)
16 paraprotein$ peripheral$ neuropath$.tw. (4)
17 chronic$ demyelinat$ neuropath$.tw. (65)
18 chronic$ inflammator$ demyelinat$ polyradiculoneuropath$.tw. (767)
19 exp Demyelinating Disease/ (103068)
20 demyelinat$ disease$.tw. (6174)
21 or/12-20 (158165)
22 Monoclonal immunoglobulinemia/ or exp Paraproteinemia/ or MGUS.tw. (90854)
23 exp Immunoglobulin A/ or exp Immunoglobulin G/ or exp PARAPROTEINS/ (138964)
24 Myelin-Associated Glycoprotein/ or MAG.tw. (4174)
25 or/22-24 (226681)
26 21 and 25 (8550)
27 ((IgG-MGUS or IgA-MGUS or IgA or IgG or Immunoglobulin G or Immunoglobulin A or paraprotein$ or monoclonal gam-
mopath$ or MAG or (myelin and glycoprotein$)) and (((demyelinat$ or peripheral) and (nerv$ or neuro$)) or (radiculoneuropath$
or polyradiculoneuropath$ or polyneuropath$ or neuropath$))).tw. (5404)
28 26 or 27 (12332)
29 (intervention or treatment).tw. (3954612)
30 exp Therapy/ (5819757)
31 exp corticosteroids/ (682376)
32 Stem cell transplantation/ (28286)
33 (stem cell adj2 transplantation).tw. (38654)
34 ((Intravenous adj2 immunoglobulin$) or ivig or interferon$1 or corticosteroid$).tw. (250495)
35 (rituximab or plasma exchange or plasmapheresis or fludarabine or cyclophosphamide or azathioprine or cyclosporine ormethotrexate
or dexamethasone or prednisolone or immunotherapy or interferon).mp. (817582)
36 or/29-35 (8357448)
37 11 and 28 and 36 (590)
38 (ms or multiple sclerosis or optic neuritis or encephalomyelitis).ti. (75877)
39 multiple sclerosis/ or optic neuritis/ or encephalomyelitis/ (83685)
40 (international MS journal or MS forum or IM).jn. (241)
41 or/38-40 (110195)
42 37 not 41 (480)
43 remove duplicates from 42 (478)
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Appendix 3. CENTRAL search strategy
#1 MeSH descriptor: [Hereditary Motor and Sensory Neuropathies] explode all trees
#2 MeSH descriptor: [Peripheral Nervous System Diseases] explode all trees
#3 (peripheral* next nervous* next system* next disease*)
#4 polyradiculoneuropath*
#5 paraprotein* next peripheral* next neuropath*
#6 chronic* next demyelinat* next neuropath*
#7 chronic* near (inflammator* next demyelinat* next polyradiculoneurop*)
#8 MeSH descriptor: [Demyelinating Diseases] explode all trees
#9 demyelinat* near disease*
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Monoclonal Gammopathies, Benign] this term only
#12 MeSH descriptor: [Paraproteinemias] explode all trees
#13 MGUS
#14 MeSH descriptor: [Paraproteins] explode all trees
#15 MeSH descriptor: [Myelin-Associated Glycoprotein] this term only
#16 MAG
#17 #11 or #12 or #13 or #14 or #15 or #16
#18 #10 and #17
#19 IgG-MGUS or IgA-MGUS or paraprotein$ or monoclonal next gammopath$ or MAG or (myelin and glycoprotein*)
#20 (((demyelinat* or peripheral) and (nerv* or neuro*)) or (radiculoneuropath* or polyradiculoneuropath* or polyneuropath* or
neuropath*))
#21 #19 and #20
#22 #18 or #21
#23 intervention or therap* or treatment*
#24 MeSH descriptor: [Therapeutics] explode all trees
#25 rituximab or plasma next exchange or plasmapheresis or fludarabine or interferon* or azathioprine or cyclosporine or methotrexate
or prednisolone
#26 stem next cell near/2 transplantation
#27 Intravenous near/2 immunoglobulin
#28 ivig or interferon* or cyclophosphamide or corticosteroid:ti and ivig or interferon* or cyclophosphamide or corticosteroid:ab
#29 MeSH descriptor: [Cyclophosphamide] explode all trees
#30 MeSH descriptor: [Dexamethasone] explode all trees
#31 MeSH descriptor: [Interferons] explode all trees
#32 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#33 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
#34 #22 and #33
#35 (“multiple sclerosis” or ms):ti
#36 (“international MS journal” or “MS forum”):so
#37 #35 or #36
#38 #34 not #37
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Appendix 4. NMD Register (CRS) search strategy
#1 MeSH DESCRIPTOR Hereditary Sensory and Motor Neuropathy Explode All [REFERENCE] [STANDARD]
#2 MeSH DESCRIPTOR Peripheral Nervous System Diseases Explode All [REFERENCE] [STANDARD]
#3 “peripheral nervous system diseases” [REFERENCE] [STANDARD]
#4 polyradiculoneuropath* [REFERENCE] [STANDARD]
#5 paraprotein* NEAR/1 “peripheral neuropathy” [REFERENCE] [STANDARD]
#6 paraprotein* NEAR/1 “peripheral neuropathies” [REFERENCE] [STANDARD]
#7 “chronic demyelinating neuropathy” or “chronic demyelinating neuropathies” [REFERENCE] [STANDARD]
#8 “chronic inflammatory demyelinating polyradiculoneuropathy” or “chronic inflammatory demyelinating polyradiculoneuropathies”
[REFERENCE] [STANDARD]
#9 MeSH DESCRIPTOR Demyelinating Diseases Explode All [REFERENCE] [STANDARD]
#10 “demyelinating disease” or “demyelinating diseases” [REFERENCE] [STANDARD]
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 [REFERENCE] [STANDARD]
#12 MeSH DESCRIPTOR Monoclonal Gammapathies, Benign [REFERENCE] [STANDARD]
#13 MeSH DESCRIPTOR Paraproteinemias Explode All [REFERENCE] [STANDARD]
#14 MeSH DESCRIPTOR Immunoglobulin A Explode All [REFERENCE] [STANDARD]
#15 MeSH DESCRIPTOR Immunoglobulin G Explode All [REFERENCE] [STANDARD]
#16 MeSH DESCRIPTOR Paraproteins Explode All [REFERENCE] [STANDARD]
#17 MeSH DESCRIPTOR Myelin-Associated Glycoprotein [REFERENCE] [STANDARD]
#18 MAG or MGUS [REFERENCE] [STANDARD]
#19 #12 or #13 or #14 or #15 or #16 or #17 or #18 [REFERENCE] [STANDARD]
#20 #11 and #19 [REFERENCE] [STANDARD]
#21 (IgG-MGUS or IgA-MGUS or IgA or IgG or “Immunoglobulin G” or “Immunoglobulin A” or paraprotein* or “monoclonal
gammopathy” or MAG or (myelin and glycoprotein*)) and (((demyelinat* or peripheral) and (nerv* or neuro*)) or (radiculoneuropath*
or polyradiculoneuropath* or polyneuropathy* or neuropath*)) [REFERENCE] [STANDARD]
#22 #20 or #21 [REFERENCE] [STANDARD]
#23 MeSH DESCRIPTOR Therapeutics Explode All [REFERENCE] [STANDARD]
#24 intervention or treatment [REFERENCE] [STANDARD]
#25 rituximab or“ plasma exchange” or plasmapheresis or fludarabine or azathioprine or cyclosporine or methotrexate or prednisolone
[REFERENCE] [STANDARD]
#26 MeSH DESCRIPTOR Cyclophosphamide Explode All [REFERENCE] [STANDARD]
#27 MeSH DESCRIPTOR Dexamethasone Explode All [REFERENCE] [STANDARD]
#28 MeSH DESCRIPTOR Interferons Explode All [REFERENCE] [STANDARD]
#29 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All [REFERENCE] [STANDARD]
#30 “stem cell” NEAR2 transplantation [REFERENCE] [STANDARD]
#31 Intravenous NEAR2 immunoglobulin or Intravenous NEAR2 immunoglobulins [REFERENCE] [STANDARD]
#32 ivig or interferon or interferons or cyclophosphamide or dexamethasone or corticosteroid* [REFERENCE] [STANDARD]
#33 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 [REFERENCE] [STANDARD]
#34 #22 and #33 [REFERENCE] [STANDARD]
#35 (#22 and #33) AND (INREGISTER) [REFERENCE] [STANDARD]
WH A T ’ S N E W
Last assessed as up-to-date: 18 January 2014.
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Date Event Description
9 April 2014 New citation required but conclusions have not changed Abraham Stork joined the review team at this update.
David Allen and Jikke-Mien Niermeijer withdrew
9 April 2014 New search has been performed New searches run to January 2014. We identified no new
trials. We revised the text throughout, assessed ’Risk of
bias’ according to currentmethodology and added a ’Sum-
mary of findings’ table
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2007
Date Event Description
28 October 2008 Amended Converted to new review format.
24 October 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
ACJS prepared the first draft of the background and protocol and prepared the data extraction form. EN-O, MPTL and NCN edited
the draft and agreed the text.
ACJS and NCN independently identified potential randomised controlled trials from the register and searches. MPTL, ACJS and
NCN independently assessed the identified trials, graded their risk of bias and performed independent data extraction.
ACJS prepared the draft of the results and the discussion. EN-O, MPTL and NCN edited the draft and agreed the text.
D E C L A R A T I O N S O F I N T E R E S T
ACJS: no disclosures.
MPTL has received honoraria for consultation from Baxter Pharmaceuticals, CSL Behring and LfB and a travel support grant from
Grifols, all manufacturers of IVIG. He was a blinded investigator in the study of Comi et al 2002.
EN-O reports personal compensation for serving in the Steering orAdvisoryBoard of Baxter, Italy,CSLBehring, Italy, Kedrion, Italy, and
Novartis, Switzerland. He received honoraria for lecturing from Baxter, Italy, CSL Behring, Italy, Grifols, Spain, and Kedrion, Italy and
travel support for scientific meetings from Baxter, CSL and Kedrion. He was the principal investigator of a RCT comparing the efficacy
of IVIg and intravenous methylprednisolone in a related condition, chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP), for which financial support was provided by Kedrion, Italy.
NCN: no disclosures.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review has a published protocol (Allen 2005). We assessed the included trial using the Cochrane ’Risk of bias’ tool (Higgins 2011),
which replaces the previous methodological assessment. We noted in the methods that for continuous outcomes we reported MD with
95% CI.
We included a ’Summary of findings’ table at this update.
At this update, two authors withdrew (D Allen and J Niermeijer). Two new authors revised the review (ACJS and NCN).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Immunoglobulin A; ∗Immunoglobulin G; Monoclonal Gammopathy of Undetermined Significance [∗therapy]; Peripheral Nervous
System Diseases [∗therapy]; Plasma Exchange
MeSH check words
Humans
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